Kidney Cancer Drugs Market

Transcription

Transparency Market
Research
Kidney Cancer Drugs Market - Global Industry Analysis,
Pipeline Analysis, Size, Share, Growth, Trends and
Forecast 2014 - 2020
Published Date
2015-01-23
82 Page Report
Buy Now
Request Sample
Press Release
Kidney Cancer Drugs Market Expected to Reach USD 4.5 Billion
Globally in 2020
Transparency Market Research
State Tower,
90, State Street, Suite 700.
Albany, NY 12207
United States
www.transparencymarketresearch.com
sales@transparencymarketresearch.com
REPORT DESCRIPTION
- Global Industry Analysis, Pipeline Analysis,
Size, Share, Growth, Trends and Forecast 2014 – 2020
Kidneys are among the most crucial organs of the human body. Their role in
regulating blood pressure and serving homeostatic functions is critical in
maintaining the balance of nutrients and toxins in the body. Kidneys serve as
natural blood filters, removing the water-soluble wastes and reabsorbing the
essential elements from the blood. Since they play such a crucial role, kidneys
require constant regeneration of dead nephrons and proper blood circulation to
maintain healthy cell growth, due to which, they are susceptible to metastasis and
cancerous tumors. Renal cell carcinoma, the most common type of kidney cancer,
is among the toughest cancers to treat, especially in the advanced stages. Until
1980’s, the treatment of kidney cancer included surgical removal of the kidneys.
The treatment later progressed to laparoscopic removal of the tumor-affected part
of the kidneys, significantly increasing the survival rate and patient comfort.
Drugs are usually given to stage four advanced renal cell carcinoma patients with
disease progression. Various forms of cancer treatment mechanism have been
implemented among the presently approved drugs for kidney cancer; these
include, VEGF (Vascular Endothelial Growth Factor) inhibitor, angiogenesis
inhibitor, cytokine therapy, and immune modulation therapy to name a few.
Browse the full Kidney Cancer Drugs Market Report at :
http://www.transparencymarketresearch.com/kidney-cancer-drugsmarket.html
2
This research report provides a detailed analysis of the global kidney cancer drugs
market and helps in understanding the various driving factors of this market. The
market overview section provides analysis of the market dynamics and trends
such as drivers, restraints, and opportunities that influence the current nature of
the market. The section also forecasts the future scenario of the market. The
executive summary gives detailed insights about the report and the market in
general. It also contains a market snapshot, which provides a glimpse into the
current scenario of the global kidney cancer drugs market. Event impact analysis
and other market dynamics tools such as market attractiveness analysis,
regulatory framework analysis, and market share analysis have also been
explained in the market overview section of the report, in order to deliver a
thorough analysis of the overall competitive scenario in the global kidney cancer
drugs market.
Get Free Sample Report Kidney Cancer Drugs Market :
http://www.transparencymarketresearch.com/sample/sample.php?
flag=S&rep_id=537
The global kidney cancer drugs market is segmented on the basis of major
branded drugs produced and geography. By major branded drugs, the market is
further segmented into the major brands approved for the indication of renal cell
carcinoma such as Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib),
Nexavar (Sorafenib), Proleukin (Aldesleukin/Interleukin-2), Sutent (Sunitinib),
Torisel (Temsirolimus), and Votrient (Pazopanib). The report also includes pipeline
analysis of the most potential drugs, which are currently in phase 2 and phase 3
trials for renal cell carcinoma indication. Considering 2013 as the base year for
estimating the market size and 2012 as the historical year, the market size
estimations for the period from 2012 to 2020 have been provided for each of the
major branded drugs mentioned above in terms of USD million. The CAGR (%) of
3
each market segment for the forecast period between 2012 to 2016 and 2016 to
2020 has also been provided along with market size estimations.
Browse the full Kidney Cancer Drugs Market press release at :
http://www.transparencymarketresearch.com/pressrelease/kidneycancer-drugs-market.htm
Geographically, the global kidney cancer drugs market has been segmented into
four major regions: North America, Europe, Asia Pacific, and Rest of World (RoW),
Russia being included in the RoW region. The market size estimations for the
period between 2012 and 2020 and market forecast for the period 2014 - 2020
have been provided for each of these regions by revenue in terms of USD million
along with the CAGR for the forecast period 2014 to 2020. This study further
offers market recommendations for market players of the global kidney cancer
drugs market, which include factors that may play a critical role in enhancing or
boosting the market share of companies in the near future. The report also
advices measures that need to be considered to achieve success for kidney
cancer drug manufacturers and marketers globally.
The report concludes with company profiles, which include key information about
the major players actively participating in the kidney cancer drugs market. The
report profiles the market players in terms of company overview, financial
overview, business strategy, recent developments, and product portfolio. The
companies featured in this report have exclusive patent rights to the following
major branded drugs: Novartis AG., F. Hoffman-La Roche., Pfizer, Inc., Bayer
Pharma AG., and GlaxoSmithKline, plc.
4
The global kidney cancer drugs market is segmented as follows:
Kidney Cancer Drugs Market, by Major Branded Drugs
Sutent (Sunitinib)
Nexavar (Sorafenib)
Afinitor (Everolimus)
Votrient (Pazopanib)
Inlyta (Axitinib)
Avastin (Bevacizumab)
Torisel (Temsirolimus)
Proleukin (Aldesleukin)
Kidney Cancer Drugs Market, by Geography
5
North America
Europe
Asia Pacific
Rest of the World (RoW)
TABLE OF CONTENT
Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 Assumptions
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Kidney Cancer Drugs Market
2.2 Comparative Analysis: Global Kidney Cancer Drugs Market, By Geography, 2013 and 2020 (Value %)
6
Chapter 3 Global Kidney Cancer Drugs Market Overview
3.1 Market Dynamics and Overview
3.2 Market Drivers
3.2.1 Rising Incidence of Kidney Cancer Expected to Boost Market Growth
3.2.2 Increasing Geriatric Population Likely to Fuel the Growth of Kidney Cancer Drugs Market
3.2.2.1.1 Global Percentage Change in the World’s Population by Age: 2010-2050
3.2.3 Approval of Novel Molecules is Expected to Drive Market Growth
3.3 Market Restraints
3.3.1 High Prices of Branded Cancer Drugs might Impede the Growth of the Market
3.3.2 Increasing Preference for Generic Drug Variants might Negatively Influence the Market Growth
3.4 Market Opportunities
3.4.1 Focusing on Emerging Markets
3.5 Event Impact Analysis
3.6 Regulatory Framework
3.7 Market Attractiveness Analysis: Global Kidney Cancer Drugs Market, by Geography
3.8 Market Share Analysis: Global Kidney Cancer Drugs Market, by Key Players, 2013 (Value %)
Chapter 4 Global Kidney Cancer Drugs Market, by Major Branded Drugs
4.1 Overview
4.1.1 Global Kidney Cancer Drugs Market Revenue, by Major Branded Drugs, 2012 – 2020 (USD Million)
4.2 Sutent (Sunitinib)
7
4.2.1 Global Sutent (Sunitinib) Market Revenue, 2012 – 2020 (USD Million)
4.3 Nexavar (Sorafenib)
4.3.1 Global Nexavar (Sorafenib) Market Revenue, 2012 – 2020 (USD Million)
4.4 Afinitor (Everolimus)
4.4.1 Global Afinitor (Everolimus) Market Revenue, 2012 – 2020 (USD Million)
4.5 Votrient (Pazopanib)
4.5.1 Global Votrient (Pazopanib) Market Revenue, 2012 – 2020 (USD Million)
4.6 Inlyta (Axitinib)
4.6.1 Global Inlyta (Axitinib) Market Revenue, 2012 – 2020 (USD Million)
4.7 Avastin (Bevacizumab)
4.7.1 Global Avastin (Bevacizumab) Market Revenue, 2012 – 2020 (USD Million)
4.8 Torisel (Temsirolimus)
4.8.1 Global Torisel (Temsirolimus) Market Revenue, 2012 – 2020 (USD Million)
4.9 Proleukin (Aldesleukin)
4.9.1 Global Proleukin (Aldesleukin) Market Revenue, 2012 – 2020 (USD Million)
Chapter 5 Global Kidney Cancer Drugs Market, Pipeline Analysis
5.1 Overview
5.1.1 Global Kidney Cancer Drugs Market Revenue, by Pipeline Drugs, 2015 – 2020 (USD Million)
5.2 Opdivo (Nivolumab) (Bristol-Myers Squibb)
5.2.1 Global Opdivo Market Revenue, 2015 – 2020 (USD Million)
8
5.3 Keytruda (Anti PD 1) (Pembrolizumab) (Merck & Co., Inc.)
5.3.1 Global Keytruda Market Revenue, 2015 – 2020 (USD Million)
5.4 Cabozantinib (XL184) (Exelixis, Inc.)
5.4.1 Global Cabozantinib Market Revenue, 2017 – 2020 (USD Million)
5.5 AGS-003 (Argus Therapeutics, Inc.)
5.5.1 Global AGS-003 Market Revenue, 2017 – 2020 (USD Million)
5.6 Dovitinib (TK1258) [Novartis AG]
5.6.1 Global Dovitinib Market Revenue, 2018 – 2020 (USD Million)
Chapter 6 Global Kidney Cancer Drugs Market, by Geography
6.1 Overview
6.1.1 Global Kidney Cancer Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million)
6.2 North America
6.2.1 North America Kidney Cancer Drugs Market Revenue, 2012–2020 (USD Million)
6.3 Europe
6.3.1 Europe Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
6.5 Rest of the World (RoW)
6.5.1 Rest of the World Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
9
Chapter 7 Recommendations
Chapter 8 Company Profiles
8.1 Bayer AG
8.1.1 Company Overview
8.1.2 Financial Overview
8.1.3 Product Portfolio
8.1.4 Business Strategy
8.1.5 Recent Developments
8.2 F. Hoffmann-La Roche, Ltd.
8.3 GlaxoSmithKline, plc
10
8.4 Novartis AG
8.5 Pfizer, Inc.
List of Figures
FIG. 1 Kidney Cancer Drugs: Market Segmentation
FIG. 2 Global Kidney Cancer Drugs Market, by Major Branded Drugs, 2013 (USD Million)
FIG. 3 Global Kidney Cancer Pipeline Drugs Market (USD Million)
FIG. 4 Comparative Analysis: Global Kidney Cancer Drugs Market, by Geography, 2013 and 2020 (Value %)
FIG. 5 Kidney Cancer Drugs Market, Drivers and Restraints
FIG. 6 Global Percentage Change in the World’s Population by Age: 2010 - 2050
FIG. 7 Major Developments in Kidney Cancer Drugs Market
11
FIG. 8 Market Attractiveness Analysis: Global Kidney Cancer Drugs Market, by Geography
FIG. 9 Market Share Analysis: Global Kidney Cancer Drugs Market, by Key Players, 2013 (Value %)
FIG. 10 Global Sutent (Sunitinib) Market Revenue, 2012 – 2020 (USD Million)
FIG. 11 Global Nexavar (Sorafenib) Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 Global Afinitor (Everolimus) Market Revenue, 2012 – 2020 (USD Million)
FIG. 13 Global Votrient (Pazopanib) Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Global Inlyta (Axitinib) Market Revenue, 2012 – 2020 (USD Million)
FIG. 15 Global Avastin (Bevacizumab) Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 Global Torisel (Temsirolimus) Market Revenue, 2012 – 2020 (USD Million)
FIG. 17 Global Proleukin (Aldesleukin) Market Revenue, 2012 – 2020 (USD Million)
FIG. 18 Global Opdivo Market Revenue, 2015 – 2020 (USD Million)
FIG. 19 Global Keytruda Market Revenue, 2015 – 2020 (USD Million)
FIG. 20 Global Cabozantinib Market Revenue, 2017 – 2020 (USD Million)
FIG. 21 Global AGS-003 Market Revenue, 2017 – 2020 (USD Million)
FIG. 22 Global Dovitinib Market Revenue, 2018 – 2020 (USD Million)
FIG. 23 North America Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
FIG. 24 Europe Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
FIG. 25 Asia Pacific Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
FIG. 26 Rest of the World Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
FIG. 27 Bayer AG: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 28 F. Hoffmann-La Roche, Ltd.: Annual Revenue, 2011 – 2013 (USD Million)
12
FIG. 29 GlaxoSmithKline, plc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 30 Annual Revenue: Novartis AG 2011 – 2013 (USD Million)
FIG. 31 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
List of Tables
TABLE 1 Market Snapshot: Global Kidney Cancer Market
TABLE 2 Stages of RCC, According to the U.S. TNM Classification
TABLE 3 Global Kidney Cancer Drugs Market Revenue, by Major Branded Drugs, 2012 – 2020 (USD Million)
TABLE 4 Global Kidney Cancer Drugs Market Revenue, by Pipeline Drugs, 2015 – 2020 (USD Million)
TABLE 5 Global Kidney Cancer Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million)
Browse All Pharmaceutical Market Research Reports @
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About Us
Transparency Market Research is a market intelligence company providing global business information
reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers.
We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use
proprietary data sources and various tools and techniques to gather, and analyze information. Our
business offerings represent the latest and the most reliable information indispensable for businesses to
sustain a competitive edge.
13
Contact
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/
Browse The Market Research Blog :
http://researchandreports.wordpress.com/ http://www.transparencymarketresearch.com
14

Kidney Cancer Drugs Market

Transcription

Similar documents

Celebrate World Kidney Day 12 March 2015

registration form (full participants)

Urology Associates of Grand Rapids, P.C. Name __________Date of Birth

MediTrim - Grand Junction`s HCG Weight Loss Clinic

Dialysis - The Kidney Foundation of Canada

UROLOGY ASSOCIATES OF KINGSPORT, P.C.

Confidential Medical History - Diagnostic Center of Medicine

Excretory System Disorders

Poszukiwanie partnerów do projektów w Programie Horyzont 2020

15 December 2014 Monday Report